Granted a PDUFA date in March 2024, if approved, sotatercept would be a first-in-class medication to address the rare and progressive disease.
This article was originally published by HCPLive®.
The US Food and Drug Administration (FDA) has accepted for priority review a new biologics license application (BLA) for sotatercept, a novel investigational activin signaling inhibitor, for the treatment of adults with pulmonary arterial hypertension (PAH).1
Announced by Merck on September 28, the FDA has set a Prescription Drug User Fee Act (PDUFA) date of March 26, 2024.
“Despite advances in the treatment of PAH over the last 2 decades, there is still a significant need to improve outcomes for patients,” said Joerg Koglin, MD, PhD, senior vice president, global clinical development, Merck Research Laboratories.1 “The FDA’s acceptance of this application is an exciting milestone in our journey to bring this novel activin signaling inhibitor to patients.”
A rare, severe disease, PAH is characterized by the narrowing of blood vessels in the lungs, leading to a significant strain on the heart. Approximately 40,000 people in the US live with the disease, the disease progresses rapidly for many patients. It has been linked to limited physical activity, heart failure, and reduced life expectancy, with a 5-year mortality rate of approximately 43%.
Sotatercept is a potential first-in-class activin signaling inhibitor biologic being studied for the treatment of PAH. The BLA for the treatment was based on data from the Phase 3 STELLAR trial. STELLAR was a pivotal phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study evaluating the safety and efficacy of sotatercept in adult patients with PAH being treated with background therapy with WHO Functional Class II or III.
Presented at the 2023 American College of Cardiology (ACC) Annual Scientific Sessions, the results showed sotatercept on top of background therapy led to a statistically significant and clinically meaningful improvement in 6-minute walk distance. In addition, sotatercept met 8 of 9 secondary endpoints, including the proportion of participants achieving multi-component improvement.2
Accompanying STELLAR, the sotatercept clinical development program includes multiple phase 2 and 3 trials across a wide range of patients. Trials are being performed in adult patients with PAH at intermediate or high risk of disease progression of mortality, as well as those with pulmonary hypertension due to left heart disease.
Sotatercept has previously been granted Breakthrough Therapy Designation and Orphan Drug designation by FDA, as well as Priority Medicines designation and Orphan Drug designation by the European Medicines Agency.
“Based on the profound improvements across primary and secondary outcome measures in the phase 3 STELLAR trial, we believe sotatercept has the potential to transform the treatment of patients with PAH,” Koglin said.1 “We look forward to working closely with the FDA to bring sotatercept to patients in need.”
In an interview with HCPLive at ACC 2023, presenting investigator Marius M. Hoeper, MD, Hannover Medical School, described the 40-meter improvement from baseline the 6-minute walk distance as due to improvement in sotatercept-treated patients, rather than deterioration in the placebo group.2
He noted the safety data have not yet been alarming, despite increased hemoglobin levels, telangiectasia, and epistaxis observed in the sotatercept arm, but clinicians should remain vigilant with sotatercept treatment.
“We expect that patients are going to be exposed to this drug for many years,” he said. “And of course, we need to be cautious and vigilant to make sure that this doesn’t develop into something more serious than what we see now.”
References
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use
April 27th 2024Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More